Format

Send to

Choose Destination
Schizophr Bull. 2015 May;41(3):559-73. doi: 10.1093/schbul/sbv002. Epub 2015 Mar 10.

The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Author information

1
guillaume.fond@gmail.com.
2
Jean Dausset Laboratory & INSERM, UMRS 940, Hôpital Saint Louis, Paris, France;
3
Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain;
4
Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Innsbruck, Austria;
5
Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Psychiatric Hospital Center Glostrup, University of Copenhagen, Faculty of Health and Medical Sciences, Denmark;
6
Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany;
7
Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK;
8
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK;
9
Department of Psychiatry, Brain Center Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands;
10
Institute of Psychiatry, King's College London, London, UK;
11
Department of Psychiatry, University of Halle, Halle, Germany.

Abstract

Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for response or side effects, none of which have been implemented in daily clinical practice. Other biomarkers exploring immunoinflammatory, oxidative, and hormonal disturbances emerged as biomarkers of first-episode psychoses in the last decades, and some of them have been associated with treatment response. In addition to pharmacogenetics, further efforts should focus on the association of emergent biomarkers with conventional treatments or with innovative therapies efficacy, where some preliminary data suggest promising results.

KEYWORDS:

antipsychotic response; biomarker; cortisol; first-episode psychosis; hormonal; inflammation; oxidative stress; pharmacogenetic

PMID:
25759473
PMCID:
PMC4393702
DOI:
10.1093/schbul/sbv002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center